There are 444 resources available
2MO - Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON
Presenter: Enriqueta Felip
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 1MO, 137MO and 2MO
Presenter: Antonio Passaro
Session: Mini Oral session 1
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 1
Resources:
Webcast
Introduction and first vote
Presenter: Rolf Stahel
Session: The pros and cons of PROs
Resources:
Slides
Webcast
PROs: We need more
Presenter: Alona Zer
Session: The pros and cons of PROs
Resources:
Slides
Webcast
Lung cancer
Presenter: Ramon Rami-Porta
Session: TNM classification: 9th edition and transition to 10th
Resources:
Slides
Webcast
IO in early disease: Clinical decisions
Presenter: Kersti Oselin
Session: IO in early disease
Resources:
Slides
Webcast
PROs: We need to simplify
Presenter: Herbert Ho Fung Loong
Session: The pros and cons of PROs
Resources:
Slides
Webcast
Thymic epithelial tumours
Presenter: Enrico Ruffini
Session: TNM classification: 9th edition and transition to 10th
Resources:
Slides
Webcast
Assessment of response and surrogate endpoints in perioperative IO trials.
Presenter: Nan Wu
Session: IO in early disease
Resources:
Slides
Webcast